Getinge B stock trades at €22.18 as investors look through recent medtech activity

Getinge AB (publ) Getinge B (SE0000202624) stock is quoted at €22.18 per share on a European venue as of August 21, 2026, providing investors with a stable reference point for the Nordic medtech name in the current market environment. Per a real-time quote overview updated on August 22, 2026, the latest traded price for Getinge B remains at €22.18, with the session showing a small positive change compared with the previous close. This keeps the share price in a mid-range corridor relative to regional health care peers by absolute price level.

Price level and recent trading context

A recent stock snapshot for Getinge AB indicates that Getinge B is trading at €22.18 per share, with the overview describing the value as the current price level for the stock on its European listing as of August 22, 2026. The same snapshot records €22.18 as the previous close, underscoring that the share price has not moved sharply from one session to the next in recent trading, and the intraday change figure is a small positive number that points to muted volatility rather than a pronounced move.

Because €22.18 is both the latest quoted price and the previous close according to the market portal view, investors can infer that Getinge B has been trading in a tight daily range around this level. With no large intraday swings indicated alongside the price, the data suggests that the stock is currently behaving like a relatively steady medtech holding in the broader European health care segment rather than a short-term trading vehicle.

Fundamental backdrop and reporting timetable

The most recent search results in this call do not present a new quarterly or annual earnings release for Getinge AB, nor do they provide explicit figures for revenue, operating income, or earnings per share tied to a clearly dated reporting period inside the current freshness window. Instead, the available context comes primarily from the live price data and company activities such as regional events and workshops that support the operational profile of the business.

In this environment, investors evaluating Getinge B on August 22, 2026 are mainly working with the steady price of €22.18 per share and an implied low-volatility profile in the near term, while awaiting the next formal financial disclosure from the company to update revenue and profit metrics. The absence of a new set of quantified fundamentals within the last nine months in the visible snippets means that any older fiscal-year figures would be purely historical references rather than current performance indicators, and they are therefore excluded from a current valuation picture.

ECMO workshop underlines clinical focus

Beyond the trading data, Getinge AB is highlighting its expertise in advanced critical-care technology through live training events in Europe. A current event page for an ECMO compact workshop in theory and practice shows that the company is using its Getinge Experience Center in Frankfurt am Main to host medical professionals for hands-on and theoretical training on extracorporeal membrane oxygenation systems. The event information underscores that Getinge continues to invest in educational outreach and clinical collaboration around ECMO, a technology used to support patients with severe respiratory or cardiac failure.

For investors, this type of workshop is a reminder that Getinge's product portfolio includes high-complexity life-support solutions that require both sophisticated hardware and clinician training. While the event page does not quantify revenues or margins, it does signal ongoing engagement with hospitals and intensive care units, which are central to Getinge's installed base and service revenue streams. In the mid-term, recurring training and customer support around ECMO can help sustain equipment utilization rates and reinforce the stickiness of Getinge's solutions within critical-care workflows.

Representative product: ECMO systems at the Experience Center

A representative product category for Getinge AB in this context is its ECMO system offering, which forms part of the company's broader portfolio of advanced cardiac and respiratory support technology. At the Getinge Experience Center in Frankfurt, the ECMO compact workshop in theory and practice is structured to expose clinicians to the practical operation of ECMO setups, including cannulation strategies, pump control, oxygenator monitoring, and patient management protocols under live or simulated conditions. This signals that Getinge is not only selling equipment but also creating an ecosystem of training and education that supports safe and effective use.

ECMO systems are capital-intensive devices that are typically purchased by tertiary hospitals and large intensive care units, often accompanied by multi-year service agreements and consumables usage. As such, ECMO contributes to a mix of one-time equipment revenue and recurring service income. When Getinge invests in workshops and experience centers, it is effectively reinforcing this product segment's long-term positioning within hospital budgets, supporting potential follow-on sales and upgrades as clinical practice evolves.

Shares at €22.18 with a steady profile

With Getinge B stock trading at €22.18 per share as of August 21, 2026, and the same price reported as the current quote on August 22, 2026, the shares are signaling a steady short-term profile on their European listing. The absence of a pronounced change versus the previous close suggests that investors have not reacted to any new, price-moving catalyst in the very latest sessions, leaving the stock anchored around this reference level while the company continues its operational initiatives such as ECMO training and customer engagement events.

Read more

Further information on Getinge AB's investor relations activities and formal financial reporting can be found through the company's own investor communications channels, which typically provide detailed data on revenue, margins, earnings per share, and guidance once new quarterly or annual results are published. These documents also outline strategic priorities in segments such as acute-care therapies, surgical workflows, and life-science equipment, offering additional context for long-term holders of Getinge B shares.

Fact box

Company: Getinge AB (publ)

ISIN: SE0000202624

Ticker: GETI B

Exchange: European listing (stock trades in EUR)

Price (as of August 21, 2026, session close): €22.18

Sector / Industry: Health care equipment and supplies

Index membership: European medtech segment